<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="named severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2. The" exact="infection" post="has now catapulted into a full-blown pandemic across the"/>
 <result pre="currently available data that shed light on possible methods for" exact="treatment" post="of COVID-19, such as antiviral drugs, corticosteroids, convalescent plasma,"/>
 <result pre="known to infect mammals such as bats can also cause" exact="infection" post="in humans, causing mild to severe respiratory ailments. The"/>
 <result pre="colds in humans, the first being rhinoviruses. The frequency of" exact="infection" post="tends to increase in the â€œautumnâ€� and winter, usually"/>
 <result pre="has been named COVID-19 [9]. The causative agent of this" exact="infection" post="is the novel SARS-CoV-2, which tends to replicate in"/>
 <result pre="countries on all continents except â€œAntarcticaâ€�. The characteristics of the" exact="infection" post="and transmission are given below: In the early days"/>
 <result pre="[2]. The time on average for its exponential growth (and" exact="infection" post="of other individuals) was observed to be about 7Â"/>
 <result pre="be approximately 5 and 12Â days from the beginning of" exact="infection" post="to their first treatment and hospital care, respectively, and"/>
 <result pre="12Â days from the beginning of infection to their first" exact="treatment" post="and hospital care, respectively, and in patients with severe"/>
 <result pre="The time from the manifestation of the disease to its" exact="diagnosis" post="in critically ill patients who eventually died was observed"/>
 <result pre="movements of infected people [6]. Channels of COVID-19 spread SARS-CoV-2" exact="infection" post="occurs through the mucosal membrane of the upper respiratory"/>
 <result pre="developmental stages of the disease [10]. The initial stage of" exact="infection" post="is usually characterized by fever, although many patients exhibit"/>
 <result pre="to a complete recovery in patients with milder illness. Initial" exact="screening" post="of the lungs of infected patients tends to reveal"/>
 <result pre="blood cells is characteristic of the initial stage of the" exact="infection" post="[10]. In some studies, an elevation in the levels"/>
 <result pre="to be elevated in patients exhibiting severe symptoms [5]. The" exact="detection" post="of SARS-CoV-2 can be achieved by rRT-PCR. Furthermore, screening"/>
 <result pre="The detection of SARS-CoV-2 can be achieved by rRT-PCR. Furthermore," exact="screening" post="of antibodies in infected individuals at the onset of"/>
 <result pre="the pathogenesis of the virus. Treatment options for COVID-19 The" exact="treatment" post="of mildly infected patients mainly depends upon self-care, and"/>
 <result pre="the patients, which demands effective intensive care and a thorough" exact="treatment" post="plan [5]. The patients are put under intensive care,"/>
 <result pre="[5]. The patients are put under intensive care, and the" exact="treatment" post="plan entails electrolyte balancing, administration of water for hydration,"/>
 <result pre="has been reported. Antibiotics are not generally used for the" exact="treatment" post="of the disease. However, patients should be examined for"/>
 <result pre="drugs in cases where there is a risk of bacterial" exact="infection" post="[10]. Traditional Chinese medicine (TCM) should be used in"/>
 <result pre="be used in combination with conventional medicines after determining the" exact="infection" post="symptoms through the conventional method of diagnosis. XueBiJing, Huo"/>
 <result pre="Jin Hua Qing Gan Granule have been tested for COVID-19" exact="treatment" post="[Song et al., 2019; Yang et al., 2020], and"/>
 <result pre="also taken into consideration previously known antiviral drugs for the" exact="treatment" post="of post-infection complications [11]. The International Clinical Trials Registry"/>
 <result pre="Currently, many new anti-COVID-19 drugs are in phase I of" exact="testing" post="[11]. Four antiviral drugs, including hydroxychloroquine (or chloroquine), favipiravir,"/>
 <result pre="IV. Currently, the CDC is recommending remdesivir as an anti-COVID-19" exact="treatment" post="for COVID-19 patients suffering from pneumonia [11]. Fig. 2"/>
 <result pre="from globally operated clinical trials investigating the most efficacious post-infection" exact="treatment" post="regimen [21]. Various antiviral medications that either are already"/>
 <result pre="candidate vaccines were being quickly optimized and prepared for initial" exact="testing" post="in human subjects [11, 22, 38, 39, 42, 43]."/>
 <result pre="is an adenosine analog drug that was produced for the" exact="treatment" post="of the Ebola virus in Africa by Gilead Science"/>
 <result pre="83]. For its use against SARS-CoV-2, the tested dosage for" exact="treatment" post="was more than 150Â mg, with intravenous administration on"/>
 <result pre="which led to the discontinuation of the drug for the" exact="treatment" post="of this disease [85]. The first case of treatment"/>
 <result pre="the treatment of this disease [85]. The first case of" exact="treatment" post="of a patient infected with SARS-CoV-2 with remdesivir was"/>
 <result pre="this patient, which corroborated the safety data from cases of" exact="treatment" post="of other viral infections with this drug [87, 88]."/>
 <result pre="[87, 88]. Nonetheless, it is important to note that the" exact="treatment" post="of three out of twelve COVID-19 patients with remdesivir"/>
 <result pre="now established remdesivir to be a promising drug for the" exact="treatment" post="of patients infected with SARS-CoV-2, and this can be"/>
 <result pre="drug azithromycin, which was given in patients to prevent bacterial" exact="infection" post="in COVID-19 cases, resulted in a stronger reduction in"/>
 <result pre="combined therapy with both drugs together with rINF-Î² for the" exact="treatment" post="of SARS-CoV-2 patients is being conducted in order to"/>
 <result pre="studies [100]. This combination was used in 2003 for the" exact="treatment" post="of SARS-CoV-1, as mentioned above, in a study by"/>
 <result pre="in those patients who received these drugs as an initial" exact="treatment" post="[101]. The considerable difference in the fatality rate after"/>
 <result pre="treatment [101]. The considerable difference in the fatality rate after" exact="treatment" post="against SARS-CoV-1 and MERS-CoV enabled the testing of lopinavir/ritonavir"/>
 <result pre="fatality rate after treatment against SARS-CoV-1 and MERS-CoV enabled the" exact="testing" post="of lopinavir/ritonavir against SARS-CoV-2 in new clinical trials conducted"/>
 <result pre="in the subjects, and the absence of any standard of" exact="treatment" post="[103â€&quot;106]. Furthermore, the administration of lopinavir/ritonavir along with other"/>
 <result pre="described with respect to treatment, dosage, and characteristics of the" exact="treatment" post="group [107â€&quot;109]. A recent clinical trial was conducted in"/>
 <result pre="which lopinavir/ritonavir combination therapy was compared to twice-a-day and standardized" exact="treatment" post="of pneumonia in COVID-19 patients [47]. The initial outcome"/>
 <result pre="until improvement was observed after administration of the therapy. Later," exact="treatment" post="success was evaluated based on fatality rates, time until"/>
 <result pre="average, and their inadequate activity in animal models for the" exact="treatment" post="of MERS-CoV infection is also not encouraging. It is"/>
 <result pre="inadequate activity in animal models for the treatment of MERS-CoV" exact="infection" post="is also not encouraging. It is also noteworthy that,"/>
 <result pre="randomized trial conducted recently, the time from the start of" exact="infection" post="to the commencement of the drug regimen was 13Â"/>
 <result pre="was 13Â days in the case of SARS-CoV-2, whereas early" exact="treatment" post="proved to be beneficial in the case of SARS-CoV-1."/>
 <result pre="empty stomach and should not be administered to patients without" exact="screening" post="them for any aggravating symptoms and observing them closely,"/>
 <result pre="findings are not yet available at this time. However, nitazoxanide" exact="treatment" post="did not lead to a decrease in the duration"/>
 <result pre="effects of tocilizumab were reported to the FDA regarding CRS" exact="treatment" post="[117]. During the recent pandemic in China, a common"/>
 <result pre="not safe to use ribavirin at the moment for the" exact="treatment" post="of COVID-19. Oseltamivir and baloxavir Oseltamivir and baloxavir are"/>
 <result pre="of different pharmacological agents against COVID-19 at various levels of" exact="infection" post="and disease development. Table 1 Pharmacological agents being investigated"/>
 <result pre="of various pharmacological agents against COVID-19 at various levels of" exact="infection" post="and disease progression Nitric oxide therapy against COVID-19 Nitric"/>
 <result pre="period, is considered to be a possible choice for the" exact="treatment" post="of infected patients. Passive antibody therapy Immunization is broadly"/>
 <result pre="CoV outbreaks, suggesting that immune serum can be used for" exact="treatment" post="of CoV infections [133]. Similarly, passive antibody therapy would"/>
 <result pre="recovered patients are the only option for this type of" exact="treatment" post="(Fig.Â 4), with the numbers of donors increasing as"/>
 <result pre="generally associated more frequently with preventative healthcare than with the" exact="treatment" post="of a specific disease, when it is used following"/>
 <result pre="likely to be most effective in the initial stages of" exact="infection" post="when the viral load is lower, allowing neutralization by"/>
 <result pre="is expected that convalescent serum can be used therapeutically for" exact="treatment" post="of COVID-19. Although its efficiency as a treatment is"/>
 <result pre="therapeutically for treatment of COVID-19. Although its efficiency as a" exact="treatment" post="is still unknown, it is known to prevent the"/>
 <result pre="Historical precedents Serum antibodies have long been used in the" exact="treatment" post="of many diseases caused by viruses, such as poliomyelitis"/>
 <result pre="mortality rates [143]. Although the efficacy of this type of" exact="treatment" post="was observed to be dependent on the viral pathogen,"/>
 <result pre="wake of recent viral outbreaks. They were employed in the" exact="treatment" post="of patients during the H1N1 influenza pandemic, where they"/>
 <result pre="from studies conducted during various viral outbreaks worldwide suggests that" exact="treatment" post="with sera from convalescent patients can improve survival [146â€&quot;149]."/>
 <result pre="the Middle Eastern countries, followed by a second wave of" exact="infection" post="in South Korea. In both of these viral outbreaks,"/>
 <result pre="many types of research investigating their potential as an effective" exact="treatment" post="option. A study conducted in Hong Kong investigated the"/>
 <result pre="A study conducted in Hong Kong investigated the effect of" exact="treatment" post="with convalescent sera on in SARS patients. Upon administration,"/>
 <result pre="in a couple of days, indicating the effectiveness of early" exact="treatment" post="[150]. Another study highlighted the decrease in the viral"/>
 <result pre="accounts of the use of convalescent serum therapy for the" exact="treatment" post="of infected patients in China [157], which shed light"/>
 <result pre="benefits Serum antibodies from recovered patients can be effective for" exact="treatment" post="of COVID-19 patients, primarily because they offer protection to"/>
 <result pre="at risk of infection. In medical practice, this type of" exact="treatment" post="is frequently employed as a precautionary measure. For treatment"/>
 <result pre="of treatment is frequently employed as a precautionary measure. For" exact="treatment" post="of HBV and rabies, immunoglobulins (HBIG and HRIG, respectively)"/>
 <result pre="are administered to infected individuals, and they are used for" exact="treatment" post="of respiratory syncytial virus (RSV) disease in susceptible children."/>
 <result pre="more likely to be useful for prevention than for rigorous" exact="treatment" post="of infection [142]. A major risk of this therapy"/>
 <result pre="to be useful for prevention than for rigorous treatment of" exact="infection" post="[142]. A major risk of this therapy is the"/>
 <result pre="the serum. This risk can be minimized through appropriate blood" exact="screening" post="practices in which donated blood is screened for infectious"/>
 <result pre="therapy is antibody-dependent enhancement (ADE) of infection. An escalation of" exact="infection" post="can occur due to various antibodies present in the"/>
 <result pre="antibodies against one type of CoV can intensify the resulting" exact="infection" post="with another CoV. Still, the intensity of the threat"/>
 <result pre="theoretical risk of passive therapy. In the case of RSV," exact="treatment" post="with antibodies before administration of the vaccine resulted in"/>
 <result pre="was done with recent use of monoclonal antibodies in the" exact="treatment" post="of Ebola [85]. Deployment and proposed use For administering"/>
 <result pre="facilities, (v) availability of serological and virological assays for the" exact="detection" post="of SARS-CoV-2 in serum and quantification of neutralization activity,"/>
 <result pre="assumed that the patients who have recuperated successfully from SARS-CoV-2" exact="infection" post="can be safely requested to donate their blood to"/>
 <result pre="negative for the virus, which can be tested through appropriate" exact="screening" post="measures, and the donated blood should also be critically"/>
 <result pre="clinical studies focusing on the evaluation of this therapy for" exact="treatment" post="of COVID-19. Previous studies have reported the amount of"/>
 <result pre="even minute concentrations can aid in the prevention or subsequent" exact="treatment" post="of infection. Therefore, prophylaxis against of infection by providing"/>
 <result pre="prevention or subsequent treatment of infection. Therefore, prophylaxis against of" exact="infection" post="by providing small doses might be efficacious, whereas larger"/>
 <result pre="of recuperated patients of COVID-19 can be employed in the" exact="treatment" post="of patients displaying onset of disease [164, 165]. Many"/>
 <result pre="the virus by treating infected patients have been advised to" exact="quarantine" post="or self-isolate, which greatly increases the disease burden on"/>
 <result pre="passive administration of antibodies, which might reduce the length of" exact="quarantine" post="and allow medical staff to continue to perform their"/>
 <result pre="the lives of COVID-19 patients by controlling the rate of" exact="infection" post="and death [166]. Generally, it has been observed that"/>
 <result pre="Mesenchymal stem cells Chinese researchers have observed that stem cell" exact="treatment" post="can reverse the symptoms in critically ill patients [167,"/>
 <result pre="(MSCs). They returned to normal life within a week. MSC" exact="treatment" post="decreased the level of inflammatory cytokines while increasing IL-10."/>
 <result pre="IL-10. The clinicians studied the behavior of MSC during the" exact="treatment" post="of COVID-19 disease. The portal of entry of SARS-CoV-2"/>
 <result pre="the use of MSCs has a promising future in the" exact="treatment" post="of COVID-19. Synthetic stem cells â€&quot; â€œLIFNanoâ€� In the"/>
 <result pre="a thousand-fold higher efficacy than cell-based LIF [171]. Using a" exact="treatment" post="model for â€œmultiple sclerosisâ€� (MS), LIFNano was effective in"/>
 <result pre="cells in EAE, demonstrating that the beneficial effects of the" exact="treatment" post="were due to the LIF produced by neural stem"/>
 <result pre="The effect of LIF on responses against the pathogenesis of" exact="infection" post="(adapted from Quinton et al. [170]). Earlier studies highlighted"/>
 <result pre="the activation of STAT3 and the role of LIF in" exact="treatment" post="[173] or its over-regulation [174], which can lead to"/>
 <result pre="newly isolated lungs with stained lung parts. Red circles indicate" exact="infection" post="in the lobes of lungs. (B) Ratios of wet:dry"/>
 <result pre="(B) Ratios of wet:dry lungs demonstrating the effect of anti-LIF" exact="treatment" post="(shown as the meanâ€‰Â±â€‰SEM. *, pâ€‰ Fig. 6 LIFNano"/>
 <result pre="the COVID-19 pandemic as well as modification and optimization of" exact="treatment" post="recommendations. COVID-19 has a low fatality rate, and deaths"/>
 <result pre="shift a major part of the ongoing research towards the" exact="treatment" post="of pneumonia in patients, which is often fatal. The"/>
 <result pre="approach to the use of an endogenous pathway for the" exact="treatment" post="of disease. In the case of pneumonia caused by"/>
 <result pre="and present a modern approach to the efficient and safe" exact="treatment" post="of critically ill patients. For its widespread application, â€œstem"/>
 <result pre="coalition to accelerate COVID-19 clinical research in resource-limited settingsLancet202039510233P1322P132510.1016/S0140-6736(20)30798-4 22.COVID-19" exact="treatment" post="and vaccine tracker. https://milkeninstitute.org/sites/default/files/2020-04/Covid19%2520Tracker%2520NEW4-3-20-2.pdf. Retrieved 3 Apr 2020 23.LiGDe"/>
 <result pre="find COVID-19 treatments acceleratesScience202036764851412141332217705 52.ChengMPLeeTCLTanDHMurthySGenerating randomized trial evidence to optimize" exact="treatment" post="in the COVID-19 pandemicCMAJ202019215E405E40732336678 53.WHO to launch multinational trial"/>
 <result pre="COVID-19-27 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---27-march-2020. Retrieved 10 Apr 2020 55.Gilead's coronavirus" exact="treatment" post="is barreling its way into new clinical trials. https://fortune.com/2020/02/26/gilead-coronavirus-treatment-clinical-trials-remdesivir/."/>
 <result pre="review on the eicacy and safety of chloroquine for the" exact="treatment" post="of COVID-19J Crit Care20205727928332173110 61.Gao J, Tian Z, Yang"/>
 <result pre="X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studies. Biosci Trends"/>
 <result pre="Phosphate Treat Novel Coronavirus Pneumonia [in Chinese]202020201010011939 63.Physicians work out" exact="treatment" post="guidelines for coronavirus. https://www.koreabiomed.com/news/articleView.html?idxno=7428. Retrieved 12 Apr 2020 64.Plaquenil"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
 <result pre="the likelihood of success: a reviewContemp Clin Trials Commun20181115616430112460 68.Vaccine" exact="testing" post="and the approval process. https://www.cdc.gov/vaccines/basics/test-approve.html. Retrieved 12 Apr 2020"/>
 <result pre="of a pyrrolo [2, 1-f][triazin4-amino] adenine C-nucleoside (GS-5734) for the" exact="treatment" post="of ebola and emerging virusesJ Med Chem20176051648166128124907 84.WarrenTKJordanRLoMKRayASMackmanRLSolovevaVSiegelDPerronMBannisterRHuiHCTherapeutic efficacy"/>
 <result pre="slow-acting antirheumatic drugsClin Pharmacokinet19932553924077904547 93.GautretPLagierJ-CParolaPMeddebLMailheMDoudierBet al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID19: results of an open-label non-randomized clinical trialInt"/>
 <result pre="virus replicationProc Natl Acad Sci200810542161191612418852458 96.ChuCChengVHungIWongMChanKChanKKaoRPoonLWongCGuanYRole of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax200459325225614985565 97.de WildeAHJochmansDPosthumaCCZevenhoven-DobbeJCvan"/>
 <result pre="(2015) Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
 <result pre="a multicentre retrospective matched cohort studyHong Kong Med J20039639940614660806 102.The" exact="diagnosis" post="and treatment guide of COVID-19 pneumonia caused by new"/>
 <result pre="retrospective matched cohort studyHong Kong Med J20039639940614660806 102.The diagnosis and" exact="treatment" post="guide of COVID-19 pneumonia caused by new coronavirus infection,"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
 <result pre="COVID-19 infection in Korea: the application of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 infected pneumonia monitored by quantitative RTPCRJ Korean"/>
 <result pre="by quantitative RTPCRJ Korean Med Sci2020356E7932056407 105.HanWQuanBGuoYZhangJLuYFengGWuQFangFChengLJiaoNLiXChenQThe course of clinical" exact="diagnosis" post="and treatment of a case infected with coronavirus disease"/>
 <result pre="RTPCRJ Korean Med Sci2020356E7932056407 105.HanWQuanBGuoYZhangJLuYFengGWuQFangFChengLJiaoNLiXChenQThe course of clinical diagnosis and" exact="treatment" post="of a case infected with coronavirus disease 2019J Med"/>
 <result pre="Immune Defic Syndr201158438521876444 111.RossignolJ-FNitazoxanide, a new drug candidate for the" exact="treatment" post="of Middle East respiratory syndrome coronavirusJ Infect Public Health20169322723027095301"/>
 <result pre="of nitazoxanide in addition to standard of care for the" exact="treatment" post="of severe acute respiratory illnessClin Infect Dis201969111903191130753384 114.KotchCBarrettDTeacheyDTTocilizumab for"/>
 <result pre="of severe acute respiratory illnessClin Infect Dis201969111903191130753384 114.KotchCBarrettDTeacheyDTTocilizumab for the" exact="treatment" post="of chimeric antigen receptor T cell-induced cytokine release syndromeExpert"/>
 <result pre="receptor T cellsClin Infect Dis201867453354029481659 117.LeRQLiLYuanWShordSSNieLHabtemariamBAPrzepiorkaDFarrellATPazdurRFDA approval summary: tocilizumab for" exact="treatment" post="of chimeric antigen receptor T cell-induced severe or life-threatening"/>
 <result pre="receptor T cell-induced severe or life-threatening cytokine release syndromeOncologist201823894329622697 118.XuXHanMLiTSunWWangDFuBZhouYZhengXYangYLiXEffective" exact="treatment" post="of severe COVID-19 patients with tocilizumabChinaXiv202020200300026v1 119.StockmanLJBellamyRGarnerPSARS: systematic review"/>
 <result pre="of severe COVID-19 patients with tocilizumabChinaXiv202020200300026v1 119.StockmanLJBellamyRGarnerPSARS: systematic review of" exact="treatment" post="effectsPLoS Med200639E34316968120 120.ChenR-cTangX-pTanS-yLiangB-lWanZ-yFangJ-qZhongNTreatment of severe acute respiratory syndrome with"/>
 <result pre="syndrome with glucosteroids: the Guangzhou experienceChest200612961441145216778260 121.LeeNChanKAHuiDSNgEKWuAChiuRWWongVWChanPKWongKWongEEffects of early corticosteroid" exact="treatment" post="on plasma SARS-associated Coronavirus RNA concentrations in adult patientsJ"/>
 <result pre="in adult patientsJ Clin Virol200431430430915494274 122.AuyeungTWLeeJSLaiWKChoiCHLeeHKLeeJSLiPCLokKHNgYYWongWMThe use of corticosteroid as" exact="treatment" post="in SARS was associated with adverse outcomes: a retrospective"/>
 <result pre="in Hong KongN Engl J Med2003348201986199412682352 128.TanELOoiEELinC-YTanHCLingAELimBStantonLWInhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg Infect Dis200410458115200845"/>
 <result pre="the inflammatory responseTrends Immunol200324947447812967670 137.CasadevallAScharffMDSerum therapy revisited: animal models of" exact="infection" post="and development of passive antibody therapyAntimicrob Agents Chemother199438816957985997 138.ParkWHTherapeutic"/>
 <result pre="141.RAMBAR AC (1946) Mumps: use of convalescent serum in the" exact="treatment" post="and prophylaxis of orchitis. Am J Dis Child 71(1):1â€&quot;13"/>
 <result pre="influenza pneumonia: a future H5N1 treatment?Ann Intern Med2006145859960916940336 144.HungIFToKKLeeC-KLeeK-LChanKYanW-WLiuRWattC-LChanW-MLaiK-YConvalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
 <result pre="Ebola virus disease in the United StatesClin Infect Dis201561449650225904375 147.KongLZhouBSuccessful" exact="treatment" post="of avian influenza with convalescent plasmaHong Kong Med J200612648917148811"/>
 <result pre="plasma for influenza A (H5N1) infectionN Engl J Med2007357141450145117914053 149.WuX-XGaoH-NWuH-BPengX-MOuH-LLiL-JSuccessful" exact="treatment" post="of avian-origin influenza A (H7N9) infection using convalescent plasmaInt"/>
 <result pre="Engl J Med2007357141450145117914053 149.WuX-XGaoH-NWuH-BPengX-MOuH-LLiL-JSuccessful treatment of avian-origin influenza A (H7N9)" exact="infection" post="using convalescent plasmaInt J Infect Dis2015413526482389 150.ChengYWongRSooYWongWLeeCNgMChanPWongKLeungCChengGUse of convalescent"/>
 <result pre="154.Van ErpEALuytjesWFerwerdaGVan KasterenPBFc-mediated antibody effector functions during respiratory syncytial virus" exact="infection" post="and diseaseFront Immunol20191054830967872 155.JenksJAGoodwinMLPermarSRThe roles of host and viral"/>
 <result pre="The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
 <result pre="influenza pneumoniaâ€&quot;a preliminary reportAm J Public Health1918810741744 164.MoYFisherDA review of" exact="treatment" post="modalities for Middle East respiratory syndromeJ Antimicrob Chemother201671123340335027585965 165.ShenCWangZZhaoFYangYLiJYuanJet"/>
</results>
